The use of Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) scans and Magnetic Resonance Imaging (MRI) to better guide high dose radiotherapy for men with high-risk prostate cancer as a means to improve clinical and quality of life outcomes.
Not Applicable
Terminated
- Conditions
- High risk prostate cancer
- Registration Number
- ACTRN12617000816358
- Lead Sponsor
- The Garvan Institute of Medical Research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Stopped early
- Sex
- Male
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie PSMA PET/MRI-guided radiotherapy in high-risk prostate cancer?
How does PSMA PET/MRI compare to standard imaging for targeting prostate cancer during radiotherapy?
Which biomarkers are used to select patients for PSMA PET/MRI-guided high-dose radiotherapy in high-risk prostate cancer?
What are the potential adverse events associated with PSMA PET/MRI-guided radiotherapy for high-risk prostate cancer patients?
Are there combination therapies involving PSMA-targeted imaging and other interventions for high-risk prostate cancer treatment?